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Introduction
Propolis is a natural substance produced by honey 
bees from different parts of plants1,2. Nowadays there 
are increasing scientific studies in view of its high 
pharmacological potential and immunomodulator 
effects3,4,5,6,7. The chemical composition is complex 
and depends on the flora in the areas where it is col-
lected2,8. However, researches indicate that phenolics 
compounds are the components with remarkable bio-
logical activity9. The green propolis, produced from 
a plant of Brazil commonly known as “Alecrim do 
Campo” (Baccharis dracunculifolia,) shows high levels 
of phenolic compounds such as artepillin C, in addi-
tion to cinnamic acid and ﬂavonoids such as pino-
banksin and kaempferol10,11,12. 
Since the efficacy of certain vaccines, especially 
those containing multiple antigens, has been some-
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Abstract
This study was designed to evaluate whether an ethanolic extract of green propolis (EEP) can interfere with production 
of specific antibodies after immunization against parvovirus (CPV) and canine coronavirus (CCoV). Mice were 
vaccinated with CPV and CCoV (0.75, 1.5 and 3 x 106 TCID50) with or without 400 µg/dose of the EEP. Twenty one days after the third dose was measured serum IgG. The co-administration of the EEP significantly enhanced serum specific 
IgG responses to CPV in animals inoculated with the highest concentration of the antigen, and had no influence on 
levels of antibodies to CCoV. The results indicate that the EEP has immunomodulatory action closely dependent on the 
type and concentration of antigen used, being able to increase the levels of antibodies to CPV.
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Resumo
Este estudo foi realizado para avaliar se extrato etanólico de própolis verde (EEP) pode interferir na produção de 
anticorpos específicos após imunização contra parvovírus (CPV) e coronavírus canino (CCoV). Camundongos foram 
vacinados com CPV e CCoV (0.75, 1.5 e 3 x 106 TCID50) com ou sem 400 µg/dose de EEP. Vinte e um dias após a terceira dose foi mensurado IgG sérica. A coadministração de EEP aumentou significativamente  os níveis de IgG específica para 
o CPV  em  animais inoculados com   a maior concentração  do  antígeno, e   não teve  influência  sobre os níveis  de 
anticorpos para CCoV. Os resultados indicam que o EEP tem ação imunomoduladora intimamente dependente do tipo 
e concentração do antígeno utilizado, sendo capaz de aumentar os níveis de anticorpos contra CPV. 
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times questioned13, the administration associated with 
an adjuvant or an appropriate immunomodulator can 
mean a better performance of these vaccines14. Thus, 
the development of vaccines will be highly beneﬁted 
with the identiﬁcation of new substances capable of 
promoting and directing to a proper immune re-
sponse. This study was designed to evaluate whether 
an ethanolic extract of green propolis (EEP) rich in 
phenolic compounds can interfere with production of 
serum specific antibodies from mice inoculated with 
different concentrations of canine parvovirus (CPV) 
and canine coronavirus (CCoV).
Material and Method
Green propolis was obtained from Nectar Farma-
ceutica Ltda. (Brazil) and stored at −20 ºC. The etha-
nolic extract was prepared as previously described15. 
After evaporation of the solvent the resulting dried 
matter was dissolved in phosphate buffer solution 
(pH 6.2), in a ﬁnal concentration of 40mg/ml. The 
chemical  composition of the green propolis extract 
was determined by high performance liquid chroma-
tography (HPLC), as described7. The HPLC analy-
sis showed high levels of the phenolic compounds 
3,5-diprenyl-4-hydroxycinnamic acid (artepillinC), 
2,2-dimethyl-6-carboxyethenyl-2H-1-benzopiran, 
3-prenyl-4-hydroxycinnamic acid, p-coumaric acid, 
caffeic acid, ferulic acid, besides cinnamic acid and 
the ﬂavonoids pinobanksin and kaempferol. In this 
sample of green propolis, the ﬂavonoids correspond-
ed to 22.37% of the dried extract.
In this study Swiss mice (Mus musculus) female, 
4-6 week-old supplied by Bioterio Central of UFPel 
(Pelotas – Brazil) were used. The animals remained 
isolated, in controlled environment with temperature 
between 22-24°C, receiving feeding and water ad li-
bitum. The experiment was approved by the UFPel 
Committee of Ethics in Animal Experimentation. The 
euthanasia was performed according to the norms es-
tablished by resolution number 714 of 20 June 2002, 
by  Conselho Federal de Medicina Veterinaria16. 
The EEP was associated with a commercial canine 
combination vaccine containing CPV modified-live and 
inactivated CCoV and adjuvanted with Al(OH)3, in ad-
dition to other attenuated virus (canine adenovirus, ca-
nine distemper virus and canine parainfluenza virus). 
The mice were allocated into eight groups of 10 ani-
mals and inoculated with the vaccine subcutaneously 
at days 0, 30 and 60. Groups one and two received 
phosphate buffered saline solution (PBS, pH 7.2) or 
PBS with EEP (400 µg/dose), respectively (negative 
controls). Group three, four and five received vaccine 
with 0.75x106, 1.5x106 e 3x106 TCID50  (tissue culture 
infections dose 50%/25 µl) of the antigens (CCoV and 
CPV), respectively. Mice from groups six, seven and 
eight were inoculated with the different doses of the 
antigens (0.75x106, 1.5x106 e 3x106 TCID50, respec-
tively) with EEP (400 µg/dose). Blood samples were 
collected on all animals from each group, on day of 
the first inoculation and 21 days after the third inocu-
lation to measure level of the antibodies. The serum 
was inactivated at 56°C for 30 minutes and stored at 
−20°C until use. 
Antibodies levels were measured by indirect ELISA 
as previously described17,18, with slight modifications. 
The supernatants of Crandell feline kidney (CrFK) cell 
infected with Cornell strain of CPV (ATCC VR-2017) 
or strain 795 Mav of CCoV (courtesy of the Laboratory 
of Virology from Universidade Federal de Santa Maria 
- Brazil), or mock infected cultures were harvested 24 
h post-infection. Cells and supernatants were frozen at 
-70 oC and clariﬁed at 250 × g for 20 min at 4 °C. Subse-
quently, the CPV supernatant was resuspended in car-
bonate buffer (Na2CO3 15 mM, NaHCO3 35 mM [pH 
9,6]). The CCoV was centrifuged for 1 h at 140000 × g 
at 4 °C. The pellets were resuspended in PBS (pH 7.2) 
and stored at -70 °C until use. 
Immunoplates were coated with CPV antigen 
(1:200) or CCoV (1:800) diluted in carbonate buf-
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fer and incubated overnight at 4°C. The plates were 
washed in phosphate-buffered saline (PBS-T) con-
taining 0,05 per cent Tween 80 (CPV) or Tween 20 
(CCoV) and then treated with a blocking solution of 
5 per cent of bovine foetal serum  for 60 minutes at 37 
°C and again washed with PBS-T. Each mice serum, 
diluted 1:50 in PBS-T, was added in duplicate and the 
plates were incubated for 60 minutes at 37 °C. After a 
washing cycle, peroxidase-conjugated goat anti-mice 
immunoglobulin IgG (Sigma Chemicals), diluted in 
PBS-T, was added to each well and the plates were in-
cubated for one hour at 37 °C. After another wash-
ing cycle, freshly prepared substrates were placed into 
each well (ortofenil diamina - OPD), for 10 minutes. 
The optical density (OD) was determined at 450 nm 
(CPV) or 405 nm (CCoV) using an ELISA Microplate 
Reader (Thermo Plate – TP reader). Each sample was 
tested in duplicate. The adjusted OD values of each 
sample were obtained by subtracting the absorbance 
of the mock antigen-coated well from that of the cor-
responding virus antigen-coated well.
Statistical analysis
Antibody titers were compared using variance 
analysis (ANOVA) with repeated measurements. The 
L.S.D. test was used to determine signiﬁcant differ-
ences (P < 0.05) among the mean of each treatment 
using the Statistix program.
Results 
Animals in groups 1 and 2 (controls without an-
tigen) did not produce specific antibodies (data not 
shown). The mean ± standard error of the mean titres 
obtained for CPV experimental group, in the pres-
ence or absence of green propolis is shown in figure 
1. There was a significant increase in levels of IgG to 
CPV (p <0.05) in the group inoculated with the high-
est concentration of antigens (3x106 TCID50) co-ad-
Figure 1 - Serum anti-CPV IgG levels (n=8/group) by indirect ELISA. Values represent mean ± S.D., 21 days after 
the third inoculation. Comparison made between groups receiving the same concentration of antigen, 
without green propolis and with 400 µg/dose of green propolis. Significant differences were designated 
as * P<0,05
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ministered with 400 µg/dose of the EEP, compared to 
animals that received only the vaccine. There were no 
statistically significant differences in antibody levels 
to CCoV in the immunized mice in the presence or 
absence of green propolis (data not shown).
Discussion 
The data obtained allowed the detection of different 
immunomodulatory properties of the EEP, depending 
on the type of antigen used. The addition of 400 µg/
dose of this extract to the vaccine increased the po-
tency of the humoral immune response to CPV when 
compared to animals that receive antigens without 
propolis. However, this ability was evident when the 
CPV was inoculated in higher dose (3x106 TCID50). 
The increase in the humoral immune response, how-
ever, was not detected when evaluated to CCoV. The 
antibody titers in this case had no statistically sig-
nificant differences in the immunized animals in the 
presence or absence of the EEP, indicating lack of abil-
ity of modulating the synthesis of antibodies to CCoV. 
Previous studies have shown stimulant activity on the 
humoral immune response when there was adminis-
tration of ethanol extracts of green propolis associated 
to antigens inactivated such as bovine and swine her-
pesvirus6,7. We note in these studies that the propolis 
was administered in the form of oil emulsion, together 
with the antigen. It is conceivable that the combination 
of oil with propolis allowed the formation of a deposit 
in the inoculation site, resulting in a slow and extend-
ed antigen and propolis release19, allowing a constant 
stimulus of the immunological system.  According to 
Cox and Coulter19 soluble substances, such as propolis, 
may be rapidly processed by the cells of the immune 
system stimulating a weak humoral immune response. 
In the present study it is possible that the way in how 
the EEP was used (not emulsified) had not allowed the 
manifestation of this action on the CPV at low concen-
tration, or on the CCoV.
The ability or lack of immunostimulating activity of 
the EEP may be associated with the different antigenic 
characteristics between these viruses. Different anti-
gens can generate different immune responses, due to 
the difference in type of APCs that encounter the anti-
gen, the density of antigen, the expression of costimu-
latory molecules and cytokine milieu. On the basis of 
cytokines profile, CD4+ T cells can be differentiated 
into Th1 and Th2 subtypes. Th1 cells secrete IFN-γ 
and other cytokines, and are mainly involved in the 
generation of cell-mediated immunity. Th2 cells are 
generally involved in humoral immunity20. These dif-
ferentiated cells are the effector arms of the immune 
system that respond to different antigens.  APCs, co-
stimulatory molecules and pro-Th1 and pro-Th2 cy-
tokines operate in a complex and concerted manner 
that can manipulate the activation of effector Th1 and 
Th2 cells21. In this context, it is possible that the pro-
duction of antibodies in this study may have been in-
fluenced by an immunomodulatory action of propolis 
exerted during the initial recognition of antigens on 
APCs or on costimulatory molecules, stimulating dif-
ferent cytokines in response to each antigen, resulting 
in increase of Th2 response to CPV. Therefore it can 
be speculated that Th2 type lymphocytes were target-
ed by this propolis after CPV exposure. Unfortunately 
it was not possible to quantify expression of pro-Th1 
cytokines to evaluate stimulation of cell-mediated im-
mune response. 
The precise mechanism of action of propolis on cells 
from the immune system is poorly understood, partly 
due to the chemical complexity and heterogeneous 
composition of propolis, resulting in controversial re-
sults11,3. Still the macrophages modulation should be 
one of the mechanisms involved22. The macrophage 
stimulation23,24, as well as the action on production 
of cytokines25 or other molecules26 was described by 
other researchers. It was also recently reported that 
the propolis increases the Toll-like receptors (TLRs) 
expression. An increased TLR-2 expression in macro-
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phages and spleen cells and increased TLR-4 expres-
sion in macrophages it was demonstrated27. This ac-
tion may be an indirect form of immunomodulation. 
TLRs are widely expressed by various cells of the im-
mune system. TLRs recognize conserved pathogen-
associated molecular patterns shared by different 
microorganisms, such as viral RNA and DNA, among 
other, playing an essential role in the innate immune 
response and in the initiation of adaptive immune 
response28. TLRs stimulation leads to upregulation 
of pro-inﬂammatory cytokines, chemokines, antimi-
crobial peptides, and additional defense molecules, in 
addition to an increase in the processing and presen-
tation of antigens to lymphocytes27,28.
The immunomodulation is still a vast field for re-
search. Given the present results we can conclude that 
the EEP can be a valuable resource for immunomodu-
lation, but its activity must be assessed for each situ-
ation and particular agent. In this study the ethanolic 
extract of green propolis had immunomodulatory ac-
tion closely dependent on the type and concentration 
of antigen used, being able to increase the levels of an-
tibodies to CPV. 
Acknowledgements
We are grateful to Coordenação de Aperfeiçoamen-
to de Pessoal de Nível Superior (CAPES) for financial 
support.  
1. CASTALDO, S.; CAPASSO, F. Propolis: an old remedy used in 
modern medicine. Fitoterapia, v. 73, n. 1, p. S1-S6, 2002.
2. PARK, Y. K.; ALENCAR, S. M.; SCAMPARINI, A. R. P.; 
AGUIAR, C. L. Própolis produzida no sul do Brasil, Argentina 
e Uruguai: evidências fitoquímicas de sua origem vegetal. 
Ciência Rural, v. 32, n. 6, p. 723-731, 2002.
3. SFORCIN, J. M. Propolis and the immune system: a review. 
Journal of Ethnopharmacology, v. 113, n, 1, p. 1-14, 2007.
4. SFORCIN, J. M.; ORSI, R. O.; BANKOVA, V. Effect of propolis, 
some isolated compounds and its source plant on antibody 
production. Journal of Ethnopharmacology, v. 98, n. 3, p. 
301-305, 2005.
5. CHU, W. H. Adjuvant effect of propolis on immunization by 
inactivated Aeromonas hydrophila in carp (Carassius auratus 
gibelio). Fish and Shellfish Immunology, v. 21, n. 1 p. 113-
117, 2006.
6. FISCHER, G.; CLEFF, M. B.; DUMMER, L. A.; PAULINO, N.; 
PAULINO, A. S.; VILELA, C. O.; CAMPOS, F. S.; STORCH, 
T.; D´AVILA V. G.; DE OLIVEIRA, J. S.; VIDOR, T. Adjuvant 
effect of green propolis on humoral immune response 
of bovines immunized with bovine herpesvirus type 5. 
Veterinary Immunology and Immunopathology, v. 116, n. 
1/2, p. 79-84, 2007.
7. FISCHER, G.; CONCEIÇÃO, F. R.; LEITE, F. P. L.; DUMMER, 
L. A.; VARGAS, G. D.; HÜBNER, S. O.; DELLAGOSTIN, 
O. A.; PAULINO, N.; PAULINO, A. S.; VIDOR, T. 
Immunomodulation produced by green propolis extract 
on humoral and cellular responses of mice immunized with 
SuHV-1. Vaccine, v. 25, n. 7, p. 1250-1256, 2007.
8. BANKOVA, V. S.; CASTRO, S. L. de; MARCUCCI, M. C. 
Propolis: recent advances in chemistry and plant origin. 
Apidologie, v. 31, n. 1, p. 3-15, 2000.
9. GALAL, A.; ABD EL-MOTAAL, A. M.; AHMED, A. M. H.; 
ZAKI, T. G. Productive performance and immune response of 
laying hens as affected by dietary propolis supplementation. 
International Journal of Poultry Sciences, v. 7, n. 3, p. 272-
278, 2008.
10. BARROS, M. P.; LEMOS, M.; MAISTROB, E. L.; LEITE M. F.; 
SOUSA, J. P. B.; BASTOS, J. K.; ANDRADE, S. F. Evaluation of 
antiulcer activity of the main phenolic acids found in Brazilian 
Green Propolis. Journal of  Ethnopharmacology, v. 120, n. 3, 
p. 372-377, 2008.
11. FISCHER, G.; HÜBNER, S. O.; VARGAS, G. D.; VIDOR, 
T. Imunomodulação pela própolis. Arquivos do Instituto 
Biológico, v. 75, n. 2, p. 247-253, 2008.
12. PAULINO, N.; ABREU, S. R. L.; UTO, Y.; KOYAMA, D.; 
NAGASAWA, H.; HORI, H.; DIRSCH, V. M.; VOLLMAR, A. 
M.; SCREMIN, A.; BRETZ, W. A. Anti-inflammatory effects of 
a bioavailable compound, Artepillin C, in Brazilian propolis. 
European Journal of Pharmacology, v. 587, p. 296-301, 2008.
13. STRASSER, A.; MAY, B.; TELTSCHER, A.; WISTRELA, 
E.; NIEDERMULLER, H. Immune modulation following 
immunization with polyvalent vaccines in dogs. Veterinary 
Immunology and Immunopathology, v. 94, n. 3/4, p. 113-
121, 2003.
14. HELDENS, J. G.; PATEL, J. R.; CHANTER, N.; TEN THIJ, 
G. J.; GRAVENDIJCK, M.; SCHIJNS, V. E.; LANGEN, A.; 
SCHETTERS, T. P. Veterinary vaccine development from an 
industrial perspective. The Veterinary Journal, v. 178, n. 1, p. 
7-20, 2008.
15. PAULINO, N.; SCREMIN, F. M.; RAICHASKI, L. B.; 
MARCUCCI, M. C.; SCREMIN, A.; CALIXTO, J. B. 
Mechanisms involved in the relaxant action of the ethanolic 
extract of propolis in the guinea-pig trachea in vitro. Journal 
of Pharmacy and Pharmacology, v. 54, n. 6, p. 1-9, 2002.
16. CONSELHO FEDERAL DE MEDICINA VETERINARIA. 
Resolução n0 714, de 20 de JUNHO de 2002. Dispões sobre 
procedimentos e métodos de eutanásia em animais. Diário 
Oficial da União (DOU), 21 de junho de 2002. Disponível 
em: < http://www.cfmv.org.br/portal/legislacao/resolucoes/
resolucao_714.pdf >.  Acesso em: 04 de junho de 2012. 
17. PHUKAN, A.; SARMA, D. K.; DEKA, D.; BORO, P. 
Standardization of ELISA for detection of canine parvovirus 
infection. Indian Veterinary Journal, v.  82, n. 4, p. 355-356, 
2005.
References
121
Braz. J. Vet. Res. Anim. Sci., São Paulo, v. 49,  n. 2,  p. 116-121, 2012
18. PRATELLI, A.; ELIA, G.; MARTELLA, V.; PALMIERI, A.; 
CIRONE, F.; TINELLI, A. CORRENTE, M.; BUONAVOGLIA, 
C. Prevalence of canine coronavirus antibodies by an enzyme-
linked immunosorbent assay in dogs in the south of Italy. 
Journal of Virology Methods, v.  102, n. 1/2, p.  67-71, 2002.
19. COX, J. C.; COULTER, A. R. Adjuvants – a classification and re-
view of their modes of action. Vaccine, v. 15, n. 3, p. 248-256, 1997.
20. ABBAS, A. K.; MURPHY, K. M.; SHER, A. Functional diversity 
of helper T lymphocytes. Nature, v. 383, p. 787-793, 1996. 
doi:10.1038/383787a0.
21. SINGH, V.; AGREWALA, J. N. Regulatory role of pro-Th1 
and pro-Th2 cytokines in modulating the activity of Th1 and 
Th2 cells when B cell and macrophages are used as antigen 
presenting cells. BMC Immunology, v. 7, p. 17, 2006. doi:   
10.1186/1471-2172-7-17.
22. ANSORGE, S.; REINHOLD, D.; LENDECKEL, U. Propolis 
and some of its constituents down-regulate DNA synthesis 
and inflammatory cytokine production but induce TGF-
beta 1 production of human immune cells. Zeitschrift für 
Naturforsch, v. 58, n. 7/8, p. 580-590, 2003.
23. DIMOV, V.; IVANOVSKA, N.; MANOLOVA, N.; BANKOVA, 
V.; NIKOLOV, N.; POPOV, S. Immunomodulatory action 
of propolis. Inﬂuence on anti-infections protection and 
macrophage function. Apidologie, v. 22, n. 2, p. 155-162, 1991.
24. SFORCIN, J. M.; KANERO, R.; FUNARI, S. R. C. Absence of 
seasonal effect on the immunomodulatory action of brazilian 
propolis on natural killer activity. The Journal of Venomous 
Animals and Toxins, v. 8, n. 1, p. 19-29, 2002.
25. HAN, S.; SUNG, K. H.; YIM, D.; LEE, S.; CHO, K.; LEE, C. 
K.; .; KIM, K. Activation of murine macrophage cell line RAW 
264.7 by Korean propolis. Archives of Pharmacol Research, v. 
25, n. 6, p. 895-902, 2002.
26. KRÓL, W.; CZUBA, Z. P.; THREADGILL, M. D.; 
CUNNINGHAM, B. D. M.; SHANI, J. Modulation of luminol-
dependent chemiluminescence of murine macrophages by 
ﬂavone and its synthetic derivatives. Drug Research, v. 45, n. 
7, p. 815-818, 1995.
27. ORSATTI, C. L.; MISSIMA, F.; PAGLIARONE, A. C.; 
BACHIEGA, T. F.; BUFALO, M. C.; ARAÚJO JR., J. R.; 
SFORCIN, J. M. Propolis immunomodulatory action In 
Vivo on Toll-like receptors 2 and 4 expression and on pro-
inflammatory cytokines production in mice. Phytotherapy 
Research, v. 24, n. 8, p. 1141-1146, 2010.
28. MEDZHITOV, R. Toll-like receptors and innate immunity. 
Nature Revews Immunology, v. 1, n. 2, p. 135-145, 2001.
